Olaparib in the management of ovarian cancer

References

• SiegelRMaJZouZJemalACancer statistics, 2014CA Cancer J Clin20146492924399786
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer Version 12015 Available from: http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdfAccessed April 28, 2015
   Google Scholar
• LuveroDMilaniALedermannJATreatment options in recurrent ovarian cancer: latest evidence and clinical potentialTher Adv Med Oncol20146522923925342990
   PubMed Web of Science ®Google Scholar
• DizonDSDupontJAndersonSTreatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experienceGynecol Oncol200391358459014675681
   PubMed Web of Science ®Google Scholar
• MarkmanMRothmanRHakesTSecond-line platinum therapy in patients with ovarian cancer previously treated with cisplatinJ Clin Oncol1991933893931999708
   PubMed Web of Science ®Google Scholar
• GoreMEFryattIWiltshawEDawsonTTreatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compoundsGynecol Oncol19903622072112404837
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NIntegrated genomic analyses of ovarian carcinomaNature2011474735360961521720365
   PubMed Web of Science ®Google Scholar
• PenningtonKPWalshTHarrellMIGermline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomasClin Cancer Res201420376477524240112
   PubMed Web of Science ®Google Scholar
• HoeijmakersJHGenome maintenance mechanisms for preventing cancerNature2001411683536637411357144
   PubMed Web of Science ®Google Scholar
• PlummerRPerspective on the pipeline of drugs being developed with modulation of DNA damage as a targetClin Cancer Res201016184527453120823148
   PubMed Web of Science ®Google Scholar
• BernsteinCBernsteinHPayneCMGarewalHDNA repair/pro- apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesisMutat Res2002511214517812052432
   PubMed Web of Science ®Google Scholar
• RisingerMAGrodenJCrosslinks and crosstalk: human cancer syndromes and DNA repair defectsCancer Cell20046653954515607958
   PubMed Web of Science ®Google Scholar
• FordDEastonDFStrattonMGenetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortiumAm J Hum Genet19986236766899497246
   PubMed Web of Science ®Google Scholar
• ChenSParmigianiGMeta-analysis of BRCA1 and BRCA2 penetranceJ Clin Oncol200725111329133317416853
   PubMed Web of Science ®Google Scholar
• TurnerNTuttAAshworthAHallmarks of ‘BRCAness’ in sporadic cancersNat Rev Cancer200441081481915510162
   PubMed Web of Science ®Google Scholar
• WalshCSTwo decades beyond BRCA1/2: homologous recombination, hereditary cancer risk and a target for ovarian cancer therapyGynecol Oncol2015137234335025725131
   PubMed Web of Science ®Google Scholar
• MoynahanMEChiuJWKollerBHJasinMBrca1 controls homology-directed DNA repairMol Cell19994451151810549283
   PubMed Web of Science ®Google Scholar
• MoynahanMEPierceAJJasinMBRCA2 is required for homology- directed repair of chromosomal breaksMol Cell20017226327211239455
   PubMed Web of Science ®Google Scholar
• O’DonovanPJLivingstonDMBRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repairCarcinogenesis201031696196720400477
   PubMed Web of Science ®Google Scholar
• FarmerHMcCabeNLordCJTargeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature2005434703591792115829967
   PubMed Web of Science ®Google Scholar
• ScullyRLivingstonDMIn search of the tumour-suppressor functions of BRCA1 and BRCA2Nature2000408681142943211100717
   PubMed Web of Science ®Google Scholar
• VenkitaramanARCancer suppression by the chromosome custodians, BRCA1 and BRCA2Science201434361781470147524675954
   PubMed Web of Science ®Google Scholar
• LordCJTuttANAshworthASynthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitorsAnnu Rev Med20156645547025341009
   PubMed Web of Science ®Google Scholar
• LordCJAshworthAThe DNA damage response and cancer therapyNature2012481738128729422258607
   PubMed Web of Science ®Google Scholar
• TuttANLordCJMcCabeNExploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancerCold Spring Harb Symp Quant Biol20057013914816869747
   PubMedGoogle Scholar
• TanDSRothermundtCThomasK“BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutationsJ Clin Oncol200826345530553618955455
   PubMed Web of Science ®Google Scholar
• CassIBaldwinRLVarkeyTMoslehiRNarodSAKarlanBYImproved survival in women with BRCA-associated ovarian carcinomaCancer20039792187219512712470
   PubMed Web of Science ®Google Scholar
• AmeJCSpenlehauerCde MurciaGThe PARP superfamilyBioessays200426888289315273990
   PubMed Web of Science ®Google Scholar
• GradwohlGMénissier de MurciaJMMolineteMThe second zinc-finger domain of poly(ADP-ribose) polymerase determines specificity for single-stranded breaks in DNAProc Natl Acad Sci U S A1990878299029942109322
   PubMed Web of Science ®Google Scholar
• RouleauMPatelAHendzelMJKaufmannSHPoirierGGPARP inhibition: PARP1 and beyondNat Rev Cancer201010429330120200537
   PubMed Web of Science ®Google Scholar
• KameshitaIMatsudaZTaniguchiTShizutaYPoly (ADP-Ribose) synthetase. Separation and identification of three proteolytic fragments as the substrate-binding domain, the DNA-binding domain, and the automodification domainJ Biol Chem19842598477047766325408
   PubMed Web of Science ®Google Scholar
• KrishnakumarRKrausWLThe PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targetsMol Cell201039182420603072
   PubMed Web of Science ®Google Scholar
• HainceJFKozlovSDawsonVLAtaxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agentsJ Biol Chem200728222164411645317428792
   PubMed Web of Science ®Google Scholar
• HainceJFMcDonaldDRodrigueAPARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sitesJ Biol Chem200828321197120818025084
   PubMed Web of Science ®Google Scholar
• SchreiberVDantzerFAmeJCde MurciaGPoly(ADP-ribose): novel functions for an old moleculeNat Rev Mol Cell Biol20067751752816829982
   PubMed Web of Science ®Google Scholar
• DavidKKAndrabiSADawsonTMDawsonVLParthanatos, a messenger of deathFront Biosci20091411161128
   PubMed Web of Science ®Google Scholar
• WangYKimNSHainceJFPoly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos)Sci Signal20114167ra2021467298
   PubMed Web of Science ®Google Scholar
• ShiehWMAméJCWilsonMVPoly(ADP-ribose) polymerase null mouse cells synthesize ADP-ribose polymersJ Biol Chem19982734630069300729804757
   PubMed Web of Science ®Google Scholar
• LjungmanMTargeting the DNA damage response in cancerChem Rev200910972929295019545147
   PubMed Web of Science ®Google Scholar
• SchultzNLopezESaleh-GohariNHelledayTPoly(ADP-ribose) polymerase (PARP1) has a controlling role in homologous recombinationNucleic Acids Res200331174959496412930944
   PubMed Web of Science ®Google Scholar
• MuraiJHuangSYDasBBTrapping of PARP1 and PARP2 by Clinical PARP InhibitorsCancer Res201272215588559923118055
   PubMed Web of Science ®Google Scholar
• LYNPARZA [package insert]Wilmington, DEAstraZeneca2014
   Google Scholar
• LiuJFKonstantinopoulosPAMatulonisUAPARP inhibitors in ovarian cancer: current status and future promiseGynecol Oncol2014133236236924607283
   PubMed Web of Science ®Google Scholar
• YangYGCortesUPatnaikSJasinMWangZQAblation of PARP1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forksOncogene200423213872388215021907
   PubMed Web of Science ®Google Scholar
• HortonJKStefanickDFNaronJMKedarPSWilsonSHPoly(ADP-ribose) polymerase activity prevents signaling pathways for cell cycle arrest after DNA methylating agent exposureJ Biol Chem200528016157731578515701627
   PubMed Web of Science ®Google Scholar
• FongPCBossDSYapTAInhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriersN Engl J Med2009361212313419553641
   PubMed Web of Science ®Google Scholar
• FongPCYapTABossDSPoly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free intervalJ Clin Oncol201028152512251920406929
   PubMed Web of Science ®Google Scholar
• AudehMWCarmichaelJPensonRTOral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialLancet2010376973724525120609468
   PubMed Web of Science ®Google Scholar
• GelmonKATischkowitzMMackayHOlaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised studyLancet Oncol201112985286121862407
   PubMed Web of Science ®Google Scholar
• KayeSBLubinskiJMatulonisUPhase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancerJ Clin Oncol201230437237922203755
   PubMed Web of Science ®Google Scholar
• LedermannJHarterPGourleyCOlaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trialLancet Oncol201415885286124882434
   PubMed Web of Science ®Google Scholar
• KaufmanBShapira-FrommerRSchmutzlerRKOlaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutationJ Clin Oncol201533324425025366685
   PubMed Web of Science ®Google Scholar
• FDA approves Lynparza to treat advanced ovarian cancer Available from: http://www.FDA.govAccessed April 28, 2015
   Google Scholar
• LiuJFTolaneySMBirrerMA Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancerEur J Cancer201349142972297823810467
   PubMed Web of Science ®Google Scholar
• LiuJFBarryWTBirrerMCombination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 studyLancet Oncol201415111207121425218906
   PubMed Web of Science ®Google Scholar
• MichalareaVLorenteDLopezJAccelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel intrapatient dose escalation design in advanced cancer patients [abstract CT323]Paper presented at: 106th Annual Meeting of the American Association for Cancer ResearchApril 18–22 2015Philadelphia, PA.
   Google Scholar
• MatulonisUAWulfGBarryWPhase I of oral BKM120 and olaparib for high-grade serous ovarian cancer or triple-negative breast cancer. Final results of the BKM120 plus olaparib cohort [abstract CT324]Paper presented at: 106th Annual Meeting of the American Association for Cancer ResearchApril 18–22 2015Philadelphia, PA
   Google Scholar
• GordonANFleagleJTGuthrieDParkinDEGoreMELacaveAJRecurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecanJ Clin Oncol200119143312332211454878
   PubMed Web of Science ®Google Scholar
• Del ConteGSessaCvon MoosRPhase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumoursBr J Cancer2014111465165925025963
   PubMed Web of Science ®Google Scholar
• LeeJMHaysJLAnnunziataCMPhase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analysesJ Natl Cancer Inst20141066dju08924842883
   PubMedGoogle Scholar
• OzaAMCibulaDBenzaquenAOOlaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trialLancet Oncol2015161879725481791
   PubMed Web of Science ®Google Scholar
• SaulERDesireeIHeatherSCaraWJamesMPhase Ib/II with expansion of patients at the MTD study of olaparib plus weekly (metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients (Suppl; abstr 5527)Paper presented at: 2014 ASCO Annual MeetingChicago, IL
   Google Scholar
• RajanACarterCAKellyRJA phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumorsClin Cancer Res20121882344235122371451
   PubMed Web of Science ®Google Scholar
• KhanOAGoreMLoriganPA phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumoursBr J Cancer2011104575075521326243
   PubMed Web of Science ®Google Scholar
• SamolJRansonMScottESafety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I studyInvest New Drugs20123041493150021590367
   PubMed Web of Science ®Google Scholar
• MolifeLRForsterMDKrebsMA phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors (Suppl; abstr 2599)Paper presented at: 2010 ASCO annual meeting2010
   Google Scholar
• MateoJFriedlanderMSessaCAdministration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formulationEur J Cancer201349s161
   Web of Science ®Google Scholar
• LedermannJHarterPGourleyCOlaparib maintenance therapy in platinum-sensitive relapsed ovarian cancerN Engl J Med2012366151382139222452356
   PubMed Web of Science ®Google Scholar
• AngJEGourleyCPowellCBEfficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional studyClin Cancer Res201319195485549323922302
   PubMed Web of Science ®Google Scholar